Chancellor Strine's View On Disclosures Evolving, Attys Say
In denying an expedited trial for a shareholder challenge to Allergan Inc.'s $958 million acquisition of MAP Pharmaceuticals Inc. last week, Delaware's top deals judge hinted yet again at a narrowing...To view the full article, register now.
Already a subscriber? Click here to view full article